Literature DB >> 2120059

Mechanism of imipenem resistance acquired by three Pseudomonas aeruginosa strains during imipenem therapy.

U Vurma-Rapp1, F H Kayser, K Hadorn, F Wiederkehr.   

Abstract

Imipenem sensitive pretherapy isolates (MICs 1-2 mg/l) and the corresponding resistant posttherapy isolates (MICs 16 mg/l) of Pseudomonas aeruginosa from three patients undergoing imipenem treatment were analyzed to establish the resistance mechanism. The identity of pyocin types, serotypes, DNA restriction endonuclease profiles and plasmid profiles strongly suggested isogenicity of pre- and posttherapy isolates. The imipenem resistant posttherapy isolates showed cross-resistance only to another carbapenem, meropenem. There were neither qualitative nor quantitative differences between pre- and posttherapy isolates in beta-lactamase production. Affinity of the penicillin-binding proteins 1A, 1B, 2, 3, 4,4' and 5 for [14C]imipenem was the same in pre- and posttherapy isolates. One-dimensional and two-dimensional gel electrophoresis of outer membrane protein preparations showed diminished expression of an outer membrane protein of about 46.5 and 47.5 kilodaltons, respectively, in the posttherapy isolates. This protein had an apparent isoelectric point of about pH 5.2 in two-dimensional gel electrophoresis. Growth in proteose peptone no. 2 broth did not reduce expression of this outer membrane protein, which spoke against its identity with the outer membrane protein D1. The permeability of the outer membrane for imipenem was reduced in the posttherapy isolates, since addition of 0.5 or 0.25 of the MIC of the permeabilizing agent ethylene-diaminetetraacetate reduced the MICs of imipenem for all isolates from each patient to the same (susceptible) level. The diminished expression of one of the outer membrane proteins might be the reason for this reduced permeability.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120059     DOI: 10.1007/bf01967212

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  35 in total

1.  Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa.

Authors:  J Trias; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

2.  Cerebrospinal fluid proteins studied by two-dimensional gel electrophoresis and immunoblotting technique.

Authors:  F Wiederkehr; A Ogilvie; D J Vonderschmitt
Journal:  J Neurochem       Date:  1987-08       Impact factor: 5.372

3.  Emergence of resistance to imipenem in Pseudomonas aeruginosa.

Authors:  M J Lynch; G L Drusano; H L Mobley
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

4.  Identification of porins in the outer membrane of Pseudomonas aeruginosa that form small diffusion pores.

Authors:  E Yoshihara; T Nakae
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

5.  Properties of the penicillin-binding proteins of Escherichia coli K12,.

Authors:  B G Spratt
Journal:  Eur J Biochem       Date:  1977-01

6.  Solubilization of the cytoplasmic membrane of Escherichia coli by the ionic detergent sodium-lauryl sarcosinate.

Authors:  C Filip; G Fletcher; J L Wulff; C F Earhart
Journal:  J Bacteriol       Date:  1973-09       Impact factor: 3.490

7.  Pseudomonas aeruginosa outer membrane permeability: isolation of a porin protein F-deficient mutant.

Authors:  T I Nicas; R E Hancock
Journal:  J Bacteriol       Date:  1983-01       Impact factor: 3.490

8.  Influence of sodium dodecyl sulphate quality on the electrophoretic mobility of the outer membrane proteins of mucoid and non-mucoid Pseudomonas aeruginosa.

Authors:  H Anwar; P A Lambert; M R Brown
Journal:  Biochim Biophys Acta       Date:  1983-12-13

9.  Heterogeneity of antibiotic resistance in mucoid isolates of Pseudomonas aeruginosa obtained from cystic fibrosis patients: role of outer membrane proteins.

Authors:  R T Irvin; J W Govan; J A Fyfe; J W Costerton
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

10.  Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant.

Authors:  B L Angus; A M Carey; D A Caron; A M Kropinski; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

View more
  6 in total

1.  Global Transcriptional Responses to Osmotic, Oxidative, and Imipenem Stress Conditions in Pseudomonas putida.

Authors:  Klara Bojanovič; Isotta D'Arrigo; Katherine S Long
Journal:  Appl Environ Microbiol       Date:  2017-03-17       Impact factor: 4.792

Review 2.  Risk factors for acquisition of multiply drug-resistant gram-negative bacteria.

Authors:  I M Gould
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

3.  Relationship between outer membrane protein profiles and resistance to ceftazidime, imipenem, and ciprofloxacin in Pseudomonas aeruginosa isolates from bacteremic patients.

Authors:  C Gimeno; D Navarro; F Savall; E Millás; M A Farga; J Garau; R Cisterna; J García-de-Lomas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

4.  Restriction endonuclease analysis of clinical Pseudomonas aeruginosa strains: useful epidemiologic data from a simple and rapid method.

Authors:  W E Maher; M Kobe; R J Fass
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

5.  Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2.

Authors:  J C Fung-Tomc; E Gradelski; B Kolek; B Minassian; M Pucci; R E Kessler; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 6.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.